Kiniksa Pharmaceuticals Ltd (KNSA)

NASDAQ
14.17
-0.35(-2.41%)
After Hours
14.17
0.00(0.00%)
- Real-time Data
  • Volume:
    544,672
  • Day's Range:
    13.74 - 14.83
  • 52 wk Range:
    7.36 - 17.19

KNSA Overview

Prev. Close
14.52
Day's Range
13.74-14.83
Revenue
158.3M
Open
14.7
52 wk Range
7.36-17.19
EPS
2.06
Volume
544,672
Market Cap
985.27M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
362,652
P/E Ratio
6.77
Beta
-0.28
1-Year Change
29.64%
Shares Outstanding
69,531,762
Next Earnings Date
Feb 21, 2023
What is your sentiment on Kiniksa Pharma?
or
Market is currently closed. Voting is open during market hours.

Kiniksa Pharmaceuticals Ltd News

Kiniksa Pharmaceuticals Ltd Analysis

Kiniksa Pharmaceuticals Ltd Company Profile

Kiniksa Pharmaceuticals Ltd Company Profile

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s portfolio of assets includes ARCALYST (rilonacept), Mavrilimumab, Vixarelimab and KPL-404. The Company's ARCALYST is an interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for treatment of recurrent pericarditis (RP), cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS), and muckle-wells syndrome (MWS) in adults and children. Its Mavrilimumab is a monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα). Its Vixarelimab is a monoclonal antibody inhibitor of signaling through oncostatin M receptor beta (OSMRβ). Its KPL-404 is a monoclonal antibody inhibitor of CD40-CD154 interaction.

Read More

Analyst Price Target

Average22.20 (+56.67% Upside)
High28.00
Low16.00
Price14.17
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellSellBuy
Technical IndicatorsStrong BuyBuyStrong SellSellStrong Buy
SummaryStrong BuyBuyStrong SellSellStrong Buy
  • I'm surprised no activity there is little activity on this stock.
    0
    • The FDA has approved. - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis- Commercial launch expected in April 2021- Kiniksa launches Kiniksa One Connect™ patient support program
      0
      • Breakthrough Therapy designation granted by the FDA for rilonacept for the treatment of recurrent pericarditis, due date is 21st March 2021 under priority review.That should help some movement
        0